ThyroidPrint is a genetic test developed by GeneproDX, a Chilean biotechnology company, to analyze thyroid nodules with indeterminate cytological results (Bethesda III and IV).

Using a molecular algorithm and real-time PCR analysis, the test can determine whether a nodule is benign with 91% sensitivity and 95% specificity, avoiding unnecessary surgery and treatments that can affect thyroid function.

Main benefits of the test

• Avoid unnecessary surgery: up to 66% of patients with indeterminate nodules can avoid surgery.
• Prevents irreversible treatments: such as total loss of the gland and permanent hormone supplementation.
• Reduces healthcare costs and time: fewer hospitalizations, fewer risks, and faster diagnosis.
• Based on international scientific evidence: validated in multiple centers and published in the journal Thyroid (impact factor 6.5).

Who can take the test?

• Patients with the following conditions:
• Indeterminate cytological diagnosis (Bethesda III or IV).
• Thyroid nodule larger than 8 mm.
• Over 18 years of age.